AMENDMENTS TO THE CLAIMS

1. (original) A compound having the structural formula



I

or a pharmaceutically acceptable salt thereof, wherein

R is

or



;

R^1, R^2, R^3, R^4 and R^5 are independently selected from the group consisting of H, alkyl and alkoxyalkyl;

R^6 is H, alkyl, hydroxyalkyl or $-CH_2F$;

R^7, R^8 and R^9 are independently selected from the group consisting of H, alkyl, alkoxy, alkylthio, alkoxyalkyl, halo and $-CF_3$;

Z is R^{10}-aryl, R^{10}-heteroaryl or



;

R^{10} is 1 to 5 substituents independently selected from the group consisting of hydrogen, alkyl, alkenyl, hydroxy, alkoxy, hydroxyalkyl, hydroxy-alkoxy, alkoxyalkyl, alkoxyalkoxy, alkoxy-alkoxy-alkyl-, (di-alkoxy)-alkyl, (hydroxy)-alkoxyalkyl, R^{15}-cycloalkyl, R^{15}-cycloalkylalkyl, cycloalkyl-oxy, cycloalkyl-O-alkoxy, alkyl-SO_2-, alkyl-SO-, halo, -CN, cyanoalkyl, $-CHF_2$, $-CF_3$, $-OCHF_2$, $-OCF_3$, $-C(O)R^{13}$, -O-alkylene-$C(O)OR^{13}$, $-C(O)O$-alkyl, $-N(R^{11})(R^{12})$, $N(R^{11})(R^{12})$-alkyl, $N(R^{11})(R^{12})$-alkoxy, $-C(O)N(R^{13})(R^{16})$, R^{11}-heteroaryl, R^{15}-heterocycloalkyl, R^{15}-heterocycloalkyl-alkyl, R^{15}-heterocycloalkyl-alkoxy, R^{15}-heterocycloalkyl-oxy, CF_3-alkylene-O-alkyl, CF_3-hydroxyalkyl, (CF_3)(hydroxy)alkoxy, cyano-alkoxy, -alkylene-C(O)-O-alkyl,

$-SO_2-N(alkyl)_2$, (cycloalkyl)hydroxyalkyl, (hydroxyalkyl)alkoxy, (dihydroxy)alkyl, (dihydroxy)alkoxy, $-C(=NOR^{17})$-alkyl and $-C(=NOR^{17})-CF_3$;

or two R^{10} groups on adjacent carbon ring atoms together form $-O-CH_2-O-$, $-O-(CH_2)_2-O-$, $-CH_2-O-(CH_2)_2-O-$, $-O-(CH_2)_2-$, $-(CH_2)_3-O-$, $-O-(CH_2)_3-O-$, $-(CH_2)_3-$, wherein the ring formed by the two R^{10} substituents and the ring carbon atoms to which they are attached is substituted by R^{16};

or two R^{10} groups on adjacent carbon ring atoms together form $-N(R^{11})-C(O)-O-$, $-N(R^{11})-C(O)-S-$, $-(CH_2)_2CH(OR^{18})-$, $-CH_2CH(OR^{18})CH_2-$, $-(CH_2)_3CH(OR^{18})-$, $-(CH_2)_2CH(OR^{18})CH_2-$, $-(CH_2)_2C(O)-$, $-CH_2C(O)CH_2-$, $-(CH_2)_3C(O)-$, $-(CH_2)_2C(O)CH_2-$, $-O(CH_2)_2CH(OR^{18})-$ or $-OCH_2CH(OR^{18})CH_2-$, wherein the ring formed by two R^{10} substituents and the ring carbon atoms to which they are attached is optionally substituted on a carbon atom by hydroxyalkyl or alkoxyalkyl;

each R^{11} is independently selected from the group consisting of H and alkyl;

each R^{12} is independently selected from the group consisting of H, alkyl, hydroxyalkyl, alkoxyalkyl, -C(O)-alkyl, -C(O)O-alkyl, (alkoxy)hydroxyalkyl, alkoxyalkyl-C(O)-, $-SO_2$alkyl, -alkylene-C(O)alkyl and -alkylene-C(O)O-alkyl;

R^{13} is H, alkyl or $-CF_3$;

R^{14} is H, alkyl, alkoxyalkyl, alkyl-C(O)- or alkoxy-C(O)-;

R^{15} is 1 to 3 substituents independently selected from the group consisting of H, alkyl, -OH, alkoxy, alkoxyalkyl and hydroxyalkyl; or two R^{15} substituents, taken together with the carbon to which they are both attached, form a $-C(=O)-$ group;

R^{16} is H, alkyl, alkoxyalkyl, OH or hydroxyalkyl;

R^{17} is H or alkyl; and

R^{18} is H or alkyl.

2. (original) A compound of claim 1 wherein R is $-C\equiv CR^6$.

3. (original) A compound of claim 2 wherein R^6 is H or alkyl.

4. (original) A compound of claim 1 wherein R^2, R^3, R^4 and R^5 are each H.

5. (original) A compound of claim 1 wherein Z is R^{10}-aryl or R^{10}-heteroaryl.

6. (original) A compound of claim 5 wherein Z is R^{10}-phenyl.

7. (original) A compound of claim 6 wherein R^{10} is 1, 2 or 3 substituents independently selected from the group consisting of H, halo, -C(O)R^{13}, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl, and cyanoalkyl.

8. (original) A compound of claim 7 comprising two R^{10} substituents wherein one R^{10} is halo and the other R^{10} is halo, -C(O)R^{13}, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

9. (original) A compound of claim 8 comprising two R^{10} substituents wherein one R^{10} is *o*-fluoro and the other R^{10} is halo, -C(O)R^{13}, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

10. (original) A compound of claim 5 wherein Z is R^{10}-heteroaryl.

11. (original) A compound of claim 10 wherein Z is R^{10}-benzoxazolyl or R^{10}-benzisoxazolyl and R^{10} is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.

12. (original) A compound of claim 11 wherein one R^{10} is fluoro and one R^{10} is methyl.

13. (original) A compound of claim 1 wherein R is –C≡CR^6, R^2, R^3, R^4 and R^5 are each H, and Z is R^{10}-aryl or R^{10}-heteroaryl.

14. (original) A compound of claim 13 wherein Z is R^{10}-phenyl and R^{10} is two substituents wherein one R^{10} is halo and the other R^{10} is halo, -C(O)R^{13}, alkyl, alkoxy, hydroxyalkyl, (cycloalkyl)hydroxyalkyl, hydroxyalkoxy, alkoxyalkoxy, alkoxyalkyl or cyanoalkyl.

15. (original) A compound of claim 13 wherein Z is R^{10}-benzoxazolyl or R^{10}-benzisoxazolyl and R^{10} is 1 or 2 substituents independently selected from the group consisting of H, halo and alkyl.

16. (original) A compound of claim 1 selected from the group consisting of












and


17. (original) A pharmaceutical composition comprising a therapeutically effective amount of a compound of claim 1 in a pharmaceutically acceptable carrier.

18. (currently amended) A method of treating Parkinson's disease or depression ~~central nervous system diseases or stroke~~, comprising administering an effective amount of a compound of formula I to a mammal in need of such treatment.

19. (canceled)

20. (canceled)

21. (original) A pharmaceutical composition comprising a therapeutically effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease in a pharmaceutically acceptable carrier.

22. (original) A method of treating Parkinson's disease comprising administering to a mammal in need of such treatment an effective amount of a combination of a compound of claim 1, and 1 to 3 other agents useful in treating Parkinson's disease.

23. (original) The method of claim 22 wherein the other agents are selected from the group consisting of L-DOPA, dopaminergic agonists, MAO-B inhibitors, DOPA decarboxylase inhibitors and COMT inhibitors.